Thomas Mourez

Thomas Mourez

Auto-generated profile, based on publicly available information

Thomas Mourez

Normandie Univ, UNIROUEN, UNICAEN, Inserm UMR 1311 DYNAMICURE, CHU Rouen, Department of Virology

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2003 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AVAstrid Vabret
Astrid Vabret
TMThomas Mourez
Thomas Mourez
SGStephanie Gouarin
Stephanie Gouarin
JPJoelle Petitjean
Joelle Petitjean
FFFrancois Freymuth
Francois Freymuth
The 2 groups of human coronaviruses (HCoVs) represented by the prototype strains HCoV 229E and HCoV OC43 are mostly known as viruses responsible for

1 August 2005 in Emerging Infectious Diseases
Verified
Journal Article
Open access
AVAstrid Vabret
Astrid Vabret
TMThomas Mourez
Thomas Mourez
JDJulia Dina
Julia Dina
LHLia van der Hoek
Lia van der Hoek
SGStéphanie Gouarin
Stéphanie Gouarin
FFFrançois Freymuth
François Freymuth
The human coronavirus NL63 (HCoV-NL63) was first identified in the Netherlands, and its circulation in France has not been investigated. We studied HCoV-NL63 infection in hospitalized children diagnosed with respiratory tract infections. From November 2002 to April 2003, we evaluated 300 respiratory specimens for HCoV-NL63. Of the 300 samples, 28 (9.3%) were positive for HCoV-NL63. The highest prevalence was found in February (18%). The main symptoms were fever (61%), rhinitis (39%), bronchiolitis (39%), digestive problems (33%), otitis (28%), pharyngitis (22%), and conjunctivitis (17%). A fragment of the spike protein gene was sequenced to determine the variety of circulating HCoV-NL63. Phylogenetic analysis indicated that strains with different genetic markers cocirculate in France.

1 July 2013 in Clinical Microbiology Reviews
Verified
Journal Article
Open access
PDF file
TMThomas Mourez
Thomas Mourez
FSFrançois Simon
François Simon
JPJean Christophe Plantier
Jean Christophe Plantier
SUMMARY The AIDS pandemic that started in the early 1980s is due to human immunodeficiency virus type 1 (HIV-1) group M (HIV-M), but apart from this major group, many divergent variants have been described (HIV-1 groups N, O, and P and HIV-2). The four HIV-1 groups arose from independent cross-species transmission of the simian immunodeficiency viruses (SIVs) SIVcpz, infecting chimpanzees, and SIVgor, infecting gorillas. This, together with human adaptation, accounts for their genomic, phylogenetic, and virological specificities. Nevertheless, the natural course of non-M HIV infection seems similar to that of HIV-M. The virological monitoring of infected patients is now possible with commercial kits, but their therapeutic management remains complex. All non-M variants were principally described for patients linked to Cameroon, where HIV-O accounts for 1% of all HIV infections; only 15 cases of HIV-N infection and 2 HIV-P infections have been reported. Despite improvements in our knowledge, many fascinating questions remain concerning the origin, genetic evolution, and slow spread of these variants. Other variants may already exist or may arise in the future, calling for close surveillance. This review provides a comprehensive, up-to-date summary of the current knowledge on these pathogens, including the historical background of their discovery; the latest advances in the comprehension of their origin and spread; and clinical, therapeutic, and laboratory aspects that may be useful for the management and the treatment of patients infected with these divergent viruses.

1 September 2001 in Journal of Virological Methods
Verified
Journal Article
Closed access
AVAstrid Vabret
Astrid Vabret
FMFranck Mouthon
Franck Mouthon
TMThomas Mourez
Thomas Mourez
SGStephanie Gouarin
Stephanie Gouarin
JPJoëlle Petitjean
Joëlle Petitjean
FFFrançois Freymuth
François Freymuth

13 January 2017 in Retrovirology
Verified
Journal Article
Open access
PDF file
FOFabienne De Oliveira
Fabienne De Oliveira
TMThomas Mourez
Thomas Mourez
AVAurélia Vessiere
Aurélia Vessiere
PNPaul-Alain Ngoupo
Paul-Alain Ngoupo
EAElodie Alessandri-Gradt
Elodie Alessandri-Gradt
JPJean Christophe Plantier
Jean Christophe Plantier
Due to the prevalence of HIV-1 group M and the endemicity of HIV-1 group O infections in Cameroon, patients may be infected with both viruses and/or with HIV-1/MO recombinant forms. Such atypical infections may be deleterious in terms of diagnosis and therapeutic management due to the high divergence of HIV-1/O. The aim of this study was to identify prospectively such atypical infections in Cameroon. Based on serological screening by env-V3 serotyping and a molecular strategy using group-specific (RT)-PCRs, we identified 10 Cameroonian patients harboring three different profiles of infection: (1) 4 HIV-1/M + O dual infections without evidence of recombinant; (2) 5 recombinants associated with one or both parental strains; and (3) 1 new recombinant form without parental strains. This work highlights the dynamic co-evolution of these two HIV groups in Cameroon that could lead to the emergence of a circulating recombinant form MO, and the need for accurate identification of such atypical infections for precise diagnosis, virological monitoring and therapeutic management with adapted tools.

1 April 2017 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
VMVirginie Morel
Virginie Morel
EMElodie Martin
Elodie Martin
CFCatherine FRANCOIS
Catherine FRANCOIS
Francois HelleFrancois Helle
Francois Helle
JFJustine Faucher
Justine Faucher
EBEtienne Brochot
Etienne Brochot
BK virus (BKV)-associated diseases in transplant recipients are an emerging issue. However, identification of the various BK virus subtypes/subgroups is a long and delicate process on the basis of currently available data. Therefore, we wanted to define a simple and effective one-step strategy for characterizing all BK virus strains from the VP1 gene sequence. Based on the analysis of 199 available complete DNA VP1 sequences, phylogenetic trees, alignments, and isolated polymorphisms were used to define an effective strategy for distinguishing the 12 different BK virus subtypes/subgroups. Based on the 12 subtypes identified from the 199 complete BKV VP1 sequences (1,089 bp), 60 mutations that can be used to differentiate these various subtypes/subgroups were identified. Some genomic areas were more variable and comprised mutational hot spots. From a subregion of only 100 bp in the VP1 region (1977 through 2076), we therefore constructed an algorithm that enabled rapid determination of all BKV subtypes/subgroups with 99% agreement (197/199) relative to the complete VP1 sequence. We called this domain of the BK viral genome the BK typing and grouping region (BKTGR). Finally, we validated our viral subtype identification process in a population of 100 transplant recipients with 100% efficiency. The new simpler method of BKV subtyping/subgrouping reported here constitutes a useful tool for future studies that will help us to more clearly understand the impact of BKV subtypes/subgroups on diagnosis, infection, and BK virus-associated diseases.